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Opacification of the left heart chambers after venous injec- 
tion of echo contrast agents with transpulmonary capabil- 
ities has been difficult to achieve because of a lack of 
availability of a biodegradable nontoxic agent that produces 
uniformly small microbubbles. SHU-508 is a new saccha- 
ride echo contrast agent that produces bubble sizes from 2 
to 8 pm in diameter, capable of traversing the pulmonary 
capillary bed and resulting in left heart contrast. The echo 
intensity produced by this agent was compared with that of 
agitated saline solution, indocyanine green and SHU-454 
(another experimental saccharide agent for right-sided con- 
trast) during 136 injections in eight dogs. Videotaped 
two-dimensional echographic images were digitized and 
analyzed with the use of videodensitometry for peak right 
and left ventricular intensity, pulmonary transit times and 
time of persistence of contrast. The highest right ventricu- 
lar intensity value (3,594 + 1,393) was achieved with 
SHU-508 (p < 0.05 compared with the other agents). The 
right ventricular contrast seen with SHU-508 also persisted 
for a longer period (22.8 f 12 s) than with the standard 
agents (p < 0.001). 
Left ventricular contrast with SHU-508 was visually 
evident in all 42 injections, whereas the peak left ventricu- 
lar intensity was 35% as bright as that produced in the 
right ventricle by the same agent. Peak left ventricular 
intensity values from SHU-508 were compared with those 
from agitated saline solution injected from the pulmonary 
capillary wedge position in four dogs. SHU-508 produced 
brighter left ventricular intensity (1,281 f 607) compared 
with that obtained with the saline-wedge technique (p < 
0.002). The left ventricular echo contrast effect persisted 
for 18.8 f 6 s compared with 8.6 + 2 s for saline solution 
(p < 0.001). The pulmonary transit time for SHU-508 was 
10.1 f 5 s for the group and appeared to vary depending on 
individual heart rates. 
Thus, SHU-508 is a new saccharide echo contrast agent 
that produces effective opacification of the left ventricular 
cavity after peripheral venous injection in dogs. 
(J Am Co11 Cardiol1989;13:1622-8) 
The ability to opacify the left heart chambers with reflected 
ultrasound from injections of indocyanine green into the 
aortic root was first described in 1968 by Gramiak and Shah 
(1). Since their pioneering efforts, other investigators have 
achieved left heart contrast by injecting agents directly into 
the left ventricle (2-4) or from the pulmonary capillary 
wedge position (5-7) or by using newer agents with the 
ability to traverse the pulmonary circulation (8-11). How- 
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ever, further advances in this area of research have been 
limited by the lack of biodegradable nontoxic contrast agents 
that have the ability to cross the pulmonary capillary bed 
(12). 
In this report, we describe our experience with a new 
intravenous saccharide echo contrast agent, SHU-508 
(Schering, Berlex Laboratories), with transpulmonary capa- 
bility for left heart contrast. Data on its ability to produce 
right and left heart echo contrast are presented and com- 
pared with use of videodensitometric analysis with data on 
other contrast agents. 
Methods 
Experimental preparation. The study was performed on 
eight male mongrel dogs weighing 20 to 34 kg (mean 24.9). 
The animals were sedated with intramuscular injections of 
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morphine sulfate, 3 mg/kg body weight, approximately 30 
min before instrumentation, then intubated with a cuffed 
endotracheal tube and ventilated at 10 to 15 breaths/min and 
400 to 500 mlimin of room air with use of a Harvard 
ventilator. Anesthesia was maintained with a combination of 
alpha-chloralose and urethane given intravenously as neces- 
sary. A 5F Millar catheter was placed in the descending 
aorta by means of a femoral artery cutdown, and was 
interfaced with a Gould 200 multichannel recorder for mon- 
itoring and recording arterial pressure. A standard lead I1 
electrocardiogram (ECG) was continuously displayed and 
recorded with cutaneous electrodes. Core temperature was 
maintained at 38 t 2°C by a heating pad. Venous access for 
administration of fluids and drugs was established with an 18 
gauge plastic cannula inserted into the femoral vein. 
A standard 18 gauge, 5 cm plastic cannula inserted 
percutaneously into a left foreleg vein served as the injection 
site for all contrast agents. The cannula was connected to a 
flush bag and injection syringes by a 2.5 ml extension tube 
and stopcocks, as described previously (13). 
Arterial blood samples were withdrawn from the side port 
of a femoral artery sheath immediately before and within 30 
s after contrast injections, and were analyzed for arterial pH. 
partial pressure of oxygen (PO,) and partial pressure of 
carbon dioxide (Pco,) with a Micro-13 blood gas analyzer 
(Instrumentation Laboratories). 
Two-dimensional echocardiographic examination. Two- 
dimensional echographic studies were performed with a 
commercially available phased array sector scanner (GE- 
PASS II) and a 3.3 MHz transducer that yielded images at 30 
frames/s over a 90” scan angle. Recording of the two- 
dimensional echocardiograms was first performed in the 
control state, with the images adjusted for optimal contrast 
and resolution. All recordings were made within a dynamic 
range of 45 dB at 12 cm depth, 38 dB overall gain and 
digitally assigned gray level values along the time-gain 
compensation “ramp.” These settings allow for a nearly 1: 1 
relation between reflected sound and video intensity. This 
technique did not always produce the ideal image on the 
video display, but was kept constant for each injection 
throughout the set of experiments. Once established during 
the baseline recordings, no changes were made in gray scale, 
depth, power, damping, reject or dynamic range controls. 
Echocardiographic images were obtained in closed chest 
dogs, with the animal in the left lateral decubitus position on 
a special table with a cutout corresponding to the chest 
region. The transducer was hand held and positioned at the 
point of maximal impulse, oriented to obtain an apical four 
chamber view of the heart and optimized for visualization of 
both the right- and left-sided chambers. All contrast injec- 
tions were recorded on 0.5 in. (1.27 cm) (VHS) videotape for 
subsequent playback and off-line computer analysis. 
Contrast agents. Four different echo contrast agents were 
selected for right heart evaluation: agitated saline solution, 
indocyanine green, SHU-454 and SHU-508. Each agent was 
prepared in the quantities and concentrations routinely used 
or recommended, and was injected in a peripheral vein in a 
standard fashion. Evaluation of left ventricular contrast with 
the transpulmonary agent (SHU-508) was compared with 
that obtained with agitated saline solution injected from a 
pulmonary artery catheter in the wedge position. The agents 
used and the methods of administration were as follows. 
Saline solution. A 10 ml aliquot of 0.9% saline solution 
was vigorously hand agitated to and fro between two sy- 
ringes connected by a three-way stopcock until the solution 
turned a grayish color. All visible bubbles were removed 
before bolus injection from the peripheral venous site. In 
addition to the peripheral venous administration, 15 injec- 
tions of 10 ml of agitated saline solution were performed in 
four dogs through a 7F Swan-Ganz pulmonary artery cath- 
eter with the balloon inflated in the wedge position, as 
verified by pressure recordings. 
Indocyunine green. A standard solution of 2.5 mg/ml 
indocyanine green (Cardio-Green) was reconstituted in 20 ml 
vials. Aliquots of 2 ml each were injected as a bolus, 
followed by an 8 ml saline flush. 
SHU-454. A biodegradable saccharide right heart con- 
trast agent, SHU-454 (Berlex Laboratories), was prepared 
by adding diluent to powder to produce a 400 mgiml suspen- 
sion. Aliquots of 2 ml were bolus injected and followed 
immediately by an 8 ml saline flush delivered over 5 s. 
SHU-454 is produced from a saccharide (galactose) pow- 
der that produces microbubbles when mixed with diluent. 
The bubble sizes in the suspension range from 5 to 15 pm 
and are intended for right heart opacification. Previous work 
from our laboratory (13) with this substance has shown that 
it produces more complete and homogeneous opacification 
of the right ventricle than does saline solution, indocyanine 
green, carbon dioxide or hydrogen peroxide. We included it 
in this experiment along with the agitated saline solution and 
indocyanine green as a reference standard for intensity of 
right ventricular opacification with which to compare SHU- 
508, a newer saccharide agent. 
SI-IU-508. A new monosaccharide contrast agent being 
developed for commercial distribution (Schering, Berlex 
Laboratories) as a left heart contrast agent was prepared just 
before injection by adding 4 ml of sterile water to SHU-508 
powder to produce a suspension with concentration of 400 
mgiml. Aliquots of 2 ml of this agent were bolus injected and 
followed by an 8 ml saline flush over 5 s. 
SHU-508 is also made from galactose, but is produced 
with a slight change in chemical composition to allow 
smaller, more uniform bubble sizes ranging from 2 to 8 pm in 
diameter, with 97% of the bubbles <6 pm by microscopic 
and laser analysis (data on file, Berlex Laboratories). These 
microbubbles are adsorbed to and stabilized by the saccha- 
ride crystals and are capable of traversing the pulmonary 
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Figure 1. Sequence of four two-dimensional echocardiographic di- 
astolic images showing contrast produced by SHU-508. 1, Four 
chamber view at time of peripheral venous injection. 2, Arrival of 
contrast medium in right heart chambers. 3, Pulmonary transmission 
of contrast, with microbubbles present in all chambers. 4, Greater 
contrast effect in left heart chambers. 
capillary bed after passing through the right heart chambers 
(Fig. 1). 
Multiple injections of each of the four contrast agents 
were performed in each dog. The sequence of injections was 
changed for each animal. After each individual injection, the 
intravenous tubing was cleared by 20 ml of saline solution 
from the reservoir bag. All injections were performed during 
suspended inspiration. Echocardiographic, ECG and hemo- 
dynamic recordings were started at least 5 s before each 
injection and were continued for 3 min or until contrast 
completely disappeared from the echo video screen. 
Videodensitometry. To accurately quantify the contrast 
effect, each videotaped injection was subjected to videoden- 
sitometric analysis with use of a commercially available 
medical image processing system (MIPRON, Kontron). This 
system consists of a computer with 64 kilobytes of program 
memory, 16 kilobytes of image memory, an array processor, 
disk drive, keyboard, data monitor, digitizing tablet and 
cursor, printer and color monitor. The injection images were 
replayed on the video screen to identify the individual 
frames representing the beginning and end of contrast ap- 
pearance. Digitization of the images was started at least one 
full cardiac cycle before right heart contrast appearance. 
Every other frame, from 16.5 s of real time recording, was 
digitized in a cyclic mode corresponding to 496 echocardio- 
graphic frames because the images were acquired at 30 
frames/s. When a low cardiac output state was present 
sufficient to result in a slow washout from the chambers, the 
analysis was continued for an additional 16.5 s. 
0 5 10 15 20 25 
Seconds 
Figure 2. Diastolic frames from the four chamber apical view 
before (left) and after (right) the arrival of SHU-508 contrast in the 
right heart. The small rectangle in the right ventricle denotes the 
position of the sample volume for videodensitometric analysis of 
intensity. The time-intensity curve displays summated gray values 
for the 35 pixels within the sample volume obtained from digitizing 
every other frame of the recording. Peak intensity, persistence times 
and pulmonary transit time were measured from these curves, as 
described in the text. Arrow indicates the point at which peripheral 
venous injection occurred. 
After analog to digital conversion, an interactive com- 
puter program was utilized that enabled an operator to 
position a rectangular region of interest within the echogram 
from which the summated gray level for all enclosed pixels 
could be measured. A sample volume of 5 x 7 pixels was 
arbitrarily chosen for all analyses. This small rectangular 
area was empirically found to give reproducible values for 
brightness. Care was taken to place the cursor in the center 
of the cardiac chamber to be evaluated, and positioned to 
avoid cardiac structures such as myocardial walls, mitral and 
tricuspid chordae and valve leaflets (Fig. 2). The summated 
gray levels for the area inside the cursor and the frame 
number were displayed and printed for each consecutive 
frame. Gray levels for each pixel were expressed on a scale 
from 0 to 255, with 255 representing the brightest value 
possible. The summated gray level within the region of 
interest before injection was measured and subtracted from 
the values obtained during contrast opacification to correct 
for background. The intensity within the sample volume was 
expressed as the summated gray level for the 35 pixels within 
the region of interest. 
By plotting the summated gray levels frame by frame, a 
time-intensity curve was obtainedfor each injection (Fig. 2). 
Measurements obtained from these curves included peak 
intensity, persistence time and pulmonary transit times. 
Peak intensity was measured as the highest gray level value 
for any frame during each injection. The persistence time 
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Table 1. Hemodynamic Effects of Contrast Injections in Eight Dogs* 
Heart Rate 
Blood Pressure (mm Hg) 
PC02 PO? 
Agent (beatsimin) Systolic Diastolic PH Itorr) itorr) 
Baseline 87.4 II9 69 7.43 28.0 84.4 
NaCl 87.2 II9 65 7.41 28.9 81.2 
KG 87.6 I18 68 7.42 29.5 82.8 
SHU-454 88. I II9 61 7.42 28.2 82.9 
SHU-508 86.5 121 67 7.42 28.0 89.4 
*Mean values for the group. p = NS for all data compared with baseline values obtained before each injection. 
ICC = indocyanine green; NaCl = agitated saline solution; Pcoz = partial pressure of carbon dioxide: PO, = partial 
pressure of oxygen; SHU-454 = right heart contrast agent; SHU-508 = transpulmonary contrast agent. 
was arbitrarily defined as the total time in seconds during 
which contrast was detectable within the sampled area, from 
the appearance of contrast to the point at which the intensity 
decreased to within 10% of baseline intensity during any 
three consecutive diastolic frames. The peak and onset 
pulmonary transit times were measured for the transpulmo- 
nary agent (SHU-508) as the time between peak right ven- 
tricular and left ventricular intensities, and the time between 
the appearance of right and left ventricular contrast effects, 
respectively. 
A qualitative visual grading scale was also used to 
describe the left ventricular opacijication achieved with 
SHU-508 and saline-wedge injections. An observer unaware 
of the agent used reviewed the tapes and assigned a grade of 
1 to 3 for homogeneity of contrast within the cavity, where 1 
= individual microbubble targets discernible, 2 = mixture of 
individual targets and homogeneous opacification and 3 = 
completely homogeneous intensity in all areas opacified. The 
extent of left ventricular cavity opacification on the four 
chamber views was also assigned a grade of 1 to 3, where 1 
= contrast limited to the area of the tips of the mitral leaflets, 
2 = contrast extending to the papillary muscle level and 3 = 
contrast extending to the left ventricular apex. 
Statistical analysis. The differences in gray level between 
background and the area of interest were expressed in 
summated gray levels. Student’s two-tailed t test for un- 
paired data was used to compare the difference in contrast 
effects among the four agents used; Student’s t test for 
unpaired data was used to compare hemodynamic data and 
blood gases with baseline measurements taken immediately 
before each injection. 
Results 
Hemodynamic effects. A total of 136 injections were 
performed in the eight dogs. All injections were well toler- 
ated. No arrhythmias were noted, except in one dog that had 
sinus bradycardia and sinus arrhythmia during the baseline 
study and throughout the experiment. There were no 
changes in ST segment or QRS configuration during admin- 
istration of any agent. Table 1 shows the overall effect of 
each contrast agent on heart rate, systolic and diastolic 
blood pressures and arterial blood gases. No significant 
change in these variables was observed during the adminis- 
tration of either of the saccharide agents or standard contrast 
agents. 
Right ventricular contrast. A typical time-intensity curve 
obtained from right ventricular videodensitometry after pe- 
ripheral venous injection of SHU-508 is shown in Figure 2. 
All agents produced right ventricular curves that demon- 
strated monoexponential decay characteristics similar to 
those of indicator-dilution curves. 
The mean background intensity recorded within the right 
ventricle for all injections was 1,086 ” 13 gray levels. The 
summated gray value obtained before each injection was 
subtracted from each subsequent frame to correct for vari- 
ations in brightness. The peak right heart contrast effect 
achieved for each contrast agent expressed as the mean gray 
level for the group of eight dogs is shown in Figure 3. The 
summated gray level values obtained during all peripheral 
venous injections ranged from 1,209 to 6,771. The maximal 
value of 6,771 with a possible value of 8,925 demonstrates 
that complete digital saturation of gray levels in the right 
heart chambers did not occur with any agent. The highest 
right ventricular intensity values were produced with the 
injection of SHU-508 (3,594 + 1,393). The other saccharide 
agent, SHU-454, also produced a greater intensity than did 
the standard agents (agitated saline solution and indocyanine 
green; p < 0.05). SHU-508 produced a 40.2% saturation of 
the gray scale, where 100% saturation is represented by a 
summated intensity value of 8,925 (255 gray levels x 35 
pixels in region of interest). SHU-454 produced the next 
greatest intensity (34.9%). 
Left ventricular contrast. A representative sequence of 
frames obtained after peripheral injection of SHU-508 is 
shown in Figure 1. The new saccharide agent produced 
complete opacification of the right heart chambers before 
targels were seen in the left ventricle. Later in the sequence, 
left ventricular intensity exceeded that of the right ventricle. 
Time-intensity plots of left heart opacijication were ob- 
tained from 42 injections of SHU-508 and 15 injections of 
agitated saline solution from the wedge position (Fig. 4). The 
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Figure 3. Graph showing peak right ventricular (RV) (solid bars) 
and left ventricular (LV) (hatched bars) contrast expressed as mean 
value 2 SD for the eight dogs. Right ventricular contrast was 
significantly greater for both saccharide agents (SHU 454 and 508) as 
compared with the standard agents (*p < 0.05). Left ventricular 
peak contrast was greater for SHU-508 (tp < 0.002) as compared 
with agitated saline solution (NaCI) injected from the pulmonary 
wedge position (PCW). Left ventricular intensity after injection of 
SHU-508 was 35% as bright as that produced in the right ventricle 
by the same agent and 62% as bright as that produced by agitated 
saline solution in the right ventricle. KG = indocyanine green. 
shape of these graphs indicates that there was a delay of 
several seconds before the arrival of contrast medium in the 
left heart chambers, and that wash-in of contrast also oc- 
curred over several seconds. The washout (descending) 
portion of these curves was also more gradual than that seen 
in the right side of the heart (Fig. 2 and 4). 
The mean intensity of the background within the left 
ventricular cavity before injections was 813 5 6 gray levels. 
The peak left heart contrast intensity values are shown in 
Figure 3. Although only SHU-508 and saline-wedge injec- 
tions produced a visual change in left heart intensity, left 
ventricular brightness was also analyzed after peripheral 
venous saline solution injections to examine the baseline 
variability of the videodensitometric technique. The mid- 
cavity left ventricular summated intensity changed by a 
mean of only 98 gray levels (or 2.8 gray levels/pixel) in this 
“control” setting. The saccharide lung-crossing agent, 
SHU-508, produced summated intensities ranging from 394 
to 3,201 gray levels in individual dogs (mean 1,281 for the 
eight dogs). This value was significantly higher than control 
values for agitated saline solution injected from a peripheral 
vein (p < 0.0001) and was also a greater intensity than that 
produced with saline solution injected from a pulmonary 
wedge position (p < 0.002) (Fig. 3). 
0 5 10 15 20 25 30 
Seconds 
Figure 4. Diastolic frames before (left) and after (right) arrival of 
left ventricular contrast after peripheral venous injection of SHU- 
508. The time-intensity plot (below) from videodensitometric analy- 
sis of left ventricular contrast shows a delay of several seconds 
between injection (arrow) and onset of contrast, and a more gradual 
wash-in and washout of contrast than was seen in the right ventricle 
(Fig. 2). Peak intensity and persistence times were measured from 
the curves, as described in the text. 
Visual grading. Visual grading of homogeneity of con- 
trast on a scale of 1 to 3 revealed a mean of 2.4 + 0.7 for 
SHU-508 (intravenous) and 1 + 0.2 for saline-(pulmonary) 
wedge injections (p < 0.0001). For extent of left ventricular 
opacification, the mean value for all SHU-508 injections was 
2.5 ? 0.6 compared with 1.6 ? 0.5 for the saline-(pulmonary) 
wedge technique (p < 0.001). Of note, the opacification 
obtained with SHU-508 in 42 injections was graded as 
completely filling the left ventricular cavity in 26 injections 
and completely homogeneous in 23 injections. The saline- 
wedge injections did not achieve a score of 3 on either scale 
during any injection. 
Persistence of contrast effect. The length of time for 
significant contrast effect was obtained from right and left 
heart time-intensity curves from all 136 injections. Both 
polysaccharide agents produced right ventricular contrast 
for longer durations than did the standard agents. SHU-508 
remained visible for 22.8 5 12 s and SHU-454 for 18.2 * 7 s 
(both p < 0.001) compared with saline solution and indocy- 
anine green. For left ventricular contrast analysis, SHU-508 
contrast was measurable for 18.8 2 6 s compared with 8.6 ? 
2 s (p < 0.001) for pulmonary wedge injections of saline 
solution. 
Pulmonary transit time. Peak transit time (or time from 
peak right ventricular to peak left ventricular contrast) 
assessed with videodensitometry was 10.1 + 5 s for the 
group of eight dogs (range 3.2 to 20.2 s). The onset transit 
times for individual dogs ranged from 1.8 to 12.4 s, with a 
mean of 5.0 +- 2 s for all SHU-508 injections. 
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Discussion 
Traditionally, opacification of the left heart chambers by 
contrast echocardiography has been achieved by injecting 
microbubbles either directly into the left heart chambers or 
from distal pulmonary artery or wedge positions (2.5,6, 
14,15). Meltzer et al. (16) showed that bubbles >I0 pm in 
size are filtered by the pulmonary capillaries, which act as a 
“sieve.” Further advancement of this field has been limited 
by lack of biodegradable nontoxic contrast agents that have 
transpulmonary capabilities and uniformly small bubble 
sizes. Recently, successful left ventricular contrast has been 
produced from peripheral venous injection of sonicated 
albumin in dogs (10) and a mixture of polygelin-lecithin in 
humans (I 1). 
Comparison of SHU-508 and other echocardiographic con- 
trast agents. Several desirable characteristics should be 
considered in the development of the ideal echo contrast 
agent for left heart opacification. First, the agent should be 
nontoxic. Second. the contrast effects should be reproduc- 
ible and fill the entire left ventricular cavity. The opacifica- 
tion should also be intense and homogeneous to aid in 
delineating endocardial borders. In this study, we have 
described our experience with a saccharide lung-crossing 
agent that is being developed for commercial use. SHU-508 
is made from a naturally occurring substance, which is of 
neutral pH and is biodegradable. The saccharide does not 
recirculate to the heart but is rapidly metabolized (data on 
file, Berlex Laboratories, June 1988). The agent produces 
intense contrast in the right heart and adequate opacification 
in the left ventricle to outline the cavity (Fig. 1). In compar- 
ison with agitated saline solution injected from the pulmo- 
nary wedge position, SHU-508 not only produced higher 
peak intensity values in the left heart, but also resulted in a 
more homogeneous effect and filled the cavity to the apex in 
most instances. Reproducibility of contrast was not directly 
evaluated in this study. There was no evidence of a biolog- 
ically significant adverse effect on the hemodynamic varia- 
bles monitored. However, only acute effects were examined. 
and further toxicity studies must be performed to consider 
the effects of these saccharides on osmolarity, metabolism 
and local effects on the vasculature of the myocardium. lung 
and brain. 
Contrast effect. Both saccharide agents resulted in higher 
right ventricular intensities than did indocyanine green or 
agitated saline solution, with gray level changes that were 
nearly 50% brighter than with agitated saline solution. In 
addition, the contrast was uniform throughout the right 
ventricular cavity and persisted for a mean period of 22 s 
with SHU-508 and 18 s for SHU-454 compared with only 8 s 
with the saline solution. A long persistence time with homo- 
geneous intensity could prove advantageous for detecting 
right to left shunts and in analyzing the “washout” of 
contrast to estimate cardiac output or right ventricular 
ejection fraction (17.18). 
SHU-508 produced a measurable and visual change in left 
ventricular intensity with all 42 injections. The left ventric- 
ular peak contrast effect was 35% as bright as that achieved 
in the right ventricle with the same agent and 61% as bright 
as the intensity of agitated saline solution in the right 
ventricle. This level of left ventricular contrast intensity is 
sufficient to visualize left heart cavities and enable contrast 
washout measurements to be made. 
Quantitation of contrast intensity. Videodensitometry 
was used to measure contrast intensity. The quantitative 
methods used here are similar to those reported by others 
(19.20) and allow for measuring and subtracting background 
intensity values from each contrast frame of the recorded 
echogram, thus correcting for differences that may exist in 
image quality or gain from subject to subject. The resulting 
pixel values, therefore, represent an absolute change in 
brightness on a scale of 0 to 255. Only the peak intensity 
values for each injection were reported here, with visual 
grading of contrast effect added to describe the homogeneity 
of brightness over the entire left ventricle and to compare 
differences among injections with regard to filling of the left 
ventricular cavity. SHU-508 proved to be far superior by 
both these criteria to saline solution injected from a pulmo- 
nary wedge position. 
Transit times. Peak pulmonary transity times ranged 
from 3.2 to 20.2 s in the 42 injections of SHU-508, whereas 
onset transit times were shorter, ranging from 1.8 to 12.4 s in 
individual dogs. These wide ranges are at least partially 
explained by significant differences in the baseline heart rate 
among the eight animals studied. The peak to peak method 
for describing the lung-crossing characteristics of dye- 
dilution indicators has been shown to produce values that 
are longer than those obtained using the appearance of 
contrast. The onset times measured in our study are in the 
range of those found in human studies with radionuclide 
methods. The pulmonary transit times were not measured 
from the wedge injections because this technique relies not 
only on the timing of injection. but also on balloon deflation 
to allow the echo contrast to pass through the pulmonary 
circulation (21). 
Clinical applications. The development of an echo con- 
trast agent with transpulmonary capabilities may be a key 
step toward enhancing the noninvasive evaluation of left 
ventricular function. In the standard echocardiographic im- 
age planes, detection of the entire endocardial left ventricu- 
lar surface is often difficult because of both signal dropout 
when the ultrasound beam is parallel to targets and artifacts 
and noise inherent in the technique (22). Opacification of the 
left ventricular cavity with microbubble targets may allow 
for better identification of the circumference of this chamber 
in patients with technically inadequate studies. However, 
subtraction techniques may be required to eliminate the 
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problem of distinguishing white contrast targets adjacent to a 
white endomyocardial image (23). 
A more useful application of left heart contrast may be in 
the calculation of left ventricular ejection fraction with use of 
videodensitometry and indicator-dilution principles (24). By 
analyzing the contrast washout curves in the left ventricle, 
an ejection fraction can be obtained that is independent of 
geometric assumptions regarding left ventricular shape and 
wall motion. This method has been previously employed in 
radionuclide angiography and contrast echocardiography 
(24,25). Left heart contrast might also provide a means for 
visually detecting and perhaps quantitating left to right 
shunts; however, it seems unlikely to supplant Doppler color 
flow imaging in this area. 
The ability to localize and image myocardial perfusion by 
contrast-enhanced two-dimensional echocardiography has 
been demonstrated (26-28). However, the reported studies 
have used agents that are injected either into the aortic root 
or directly into the coronary arteries. Theoretically, this may 
be accomplished with an injection of an echo contrast agent 
with transpulmonary capabilities if adequate contrast effect 
is achieved in the left heart chambers. The saccharide 
lung-crossing agent SHU-508 did not produce visually evi- 
dent myocardial enhancement at the doses (2 ml) and con- 
centrations (400 mg/ml) employed in our study. However, it 
is possible that small increases in myocardial intensity 
occurred that could be measured with videodensitometry or 
digital subtraction techniques. Because of the many poten- 
tial uses of contrast echocardiography, work will continue 
toward the development of an ideal contrast agent. 
We thank Jo Ann Neal for preparing the manuscript. 
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